Malaria is an
infectious disease caused by the mosquito. The disease is spread by the bite of
the mosquito. After sucking blood from human beings the mosquito releases Plasmodium
parasite which actually
causes the disease.
A clinical trial was
done to find out the comparative effectiveness of pyronaridine - artesunate
single pill drug and mefloquine plus artesunate combination as separate pills
for the treatment of Plasmodium
According to a study
the fixed dose of the combination of pyronaridine-artesunate was found to be as
effective as artesunate plus mefloquine in curing malarial infection.
Rueangweerayut and his colleagues from the Mae Sot general Hospital from Tak,
Thailand randomly took 1,271 patients from Asian and African region. These
patients had confirmed uncomplicated Plasmodium
Pyronaridine is a
widely used anti-malarial drug in China while artesunate and other identical
artemisinin-based agents are used for treating malaria in the malaria prone
A fixed dose of 60mg
artesunate plus 180mg pyronaridine was given to 848 patients while 423 patients
were given 100mg artesunate plus 250mg mefloquine were administered for three
Depending upon the
parasitological and proper clinical response on 28th day, it was seen that both
the groups had similar efficacy in treating malaria. The
pyronaridine-artesunate showed 99.2 percent efficacy and mefloquine-artesunate
had 97.8 percent efficacy in treating the ailment.
On the 42nd day, the
efficacy was found to be 83.1 percent with pyronaridine-artesunate group and
83.9 percent in mefloquine-artesunate group.
In the 211 Cambodian
patients, both groups revealed that artemisinin took longer to clear the
parasite. Incidentally, the Cambodian region is a low-transmission region for Plasmodium falciparum
which means that
its inhabitants are less likely to be immune to the malaria parasite as
compared to those living elsewhere and have higher incidence of infection.
stated, "Fixed-dose pyronaridine-artesunate was efficacious in the treatment of
uncomplicated P. falciparum
In Cambodia, extended parasite clearance times were suggestive of in vivo
resistance to artemisinin."
They concluded that
pyronaridine-artesunate has greater potential for treating P. falciparum
This study was
supported and funded by Shin Poong Pharmaceutical co. and the Medicines for
Pyronaridine-Artesunate versus Mefloquine plus
Artesunate for Malaria; Ronnatrai et al; N Engl J Med 2012; 366:1298-1309April